Monoclonal antibody-based immunotherapy is now considered to be a main component of
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …

It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …

Pharmacological and cellular treatment of cancer is changing dramatically with benefits for
patient outcome and comfort, but also with new toxicity profiles. The majority of adverse …

Antibodies are important therapeutic agents for cancer. Recently, it has become clear that
antibodies possess several clinically relevant mechanisms of action. Many clinically useful …

Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination
with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment, followed by …

Purpose New treatments are needed for patients with fludarabine-and alemtuzumab-
refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory …

We have used homologous recombination in ES cells to engineer B cell-deficient mice that
are incapable of expressing endogenous immunoglobulin heavy and kappa light chain …

Monocytes in peripheral blood circulation are the precursor of essential cells that control
tumor progression, that include tumor-associated macrophages (TAMs), dendritic cells …

Over the past two decades, technologies have emerged for generating monoclonal
antibodies (MAbs) derived from human immunoglobulin gene sequences. These fully …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …